

Eva Szegezdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5128215/publications.pdf>

Version: 2024-02-01

71
papers

10,485
citations

147801

31
h-index

98798

67
g-index

72
all docs

72
docs citations

72
times ranked

21526
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Mediators of endoplasmic reticulum stress-induced apoptosis. <i>EMBO Reports</i> , 2006, 7, 880-885.	4.5	2,033
3	Caspase-12 and ER-Stress-Mediated Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 186-194.	3.8	427
4	Transglutaminase 2 ^{-/-} mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7812-7817.	7.1	249
5	TRAIL receptor signalling and modulation: Are we on the right TRAIL?. <i>Cancer Treatment Reviews</i> , 2009, 35, 280-288.	7.7	248
6	Bcl-2 family on guard at the ER. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 296, C941-C953.	4.6	222
7	The mitochondrial death pathway: a promising therapeutic target in diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1004-1033.	3.6	211
8	ER stress contributes to ischemia-induced cardiomyocyte apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 1406-1411.	2.1	185
9	Metabolic Flexibility Permits Mesenchymal Stem Cell Survival in an Ischemic Environment. <i>Stem Cells</i> , 2008, 26, 1325-1336.	3.2	165
10	Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8634-8639.	7.1	151
11	An Unfractionated Fucoidan from <i>Ascophyllum nodosum</i> : Extraction, Characterization, and Apoptotic Effects in Vitro. <i>Journal of Natural Products</i> , 2011, 74, 1851-1861.	3.0	121
12	Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling. , 2013, 140, 186-199.		93
13	Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 801-810.	2.1	89
14	Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-2. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 509-520.	3.6	78
15	N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. <i>Cell Death and Differentiation</i> , 2017, 24, 500-510.	11.2	75
16	TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. <i>Oncotarget</i> , 2017, 8, 9974-9985.	1.8	68
17	Mechanisms of ER Stress-Mediated Mitochondrial Membrane Permeabilization. <i>International Journal of Cell Biology</i> , 2010, 2010, 1-9.	2.5	67
18	Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. <i>Cell Death and Disease</i> , 2013, 4, e702-e702.	6.3	66

#	ARTICLE	IF	CITATIONS
19	Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines. <i>Current Pharmaceutical Design</i> , 2014, 20, 189-200.	1.9	65
20	Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. <i>Cell Death and Disease</i> , 2010, 1, e83-e83.	6.3	63
21	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	3.5	63
22	Cytokine-induced cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-2. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 591-606.	3.6	56
23	DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design. <i>Journal of Biological Chemistry</i> , 2008, 283, 20560-20568.	3.4	56
24	Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. <i>Oncogene</i> , 2016, 35, 1261-1270.	5.9	54
25	Involvement of planned cell death of necroptosis in cancer treatment by nanomaterials: Recent advances and future perspectives. <i>Journal of Controlled Release</i> , 2019, 299, 121-137.	9.9	47
26	Stem cells are resistant to TRAIL receptor-mediated apoptosis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 4409-4414.	3.6	44
27	The Janus Face of Death Receptor Signaling during Tumor Immunoediting. <i>Frontiers in Immunology</i> , 2016, 7, 446.	4.8	42
28	Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities. <i>Blood Reviews</i> , 2021, 50, 100850.	5.7	40
29	Apoptosis-linked in vivo regulation of the tissue transglutaminase gene promoter. <i>Cell Death and Differentiation</i> , 2000, 7, 1225-1233.	11.2	38
30	Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion via regulation of Bim. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2482-2496.	3.6	38
31	Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. <i>British Journal of Cancer</i> , 2009, 100, 1415-1424.	6.4	35
32	Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. <i>British Journal of Cancer</i> , 2010, 102, 754-764.	6.4	34
33	TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. <i>British Journal of Cancer</i> , 2006, 94, 398-406.	6.4	31
34	Activation-induced apoptosis and cell surface expression of Fas (CD95) ligand are reciprocally regulated by retinoic acid receptor α and β and involve nur77 in T cells. <i>European Journal of Immunology</i> , 2001, 31, 1382-1391.	2.9	30
35	Ligation of Retinoic Acid Receptor α Regulates Negative Selection of Thymocytes by Inhibiting Both DNA Binding of nur77 and Synthesis of Bim. <i>Journal of Immunology</i> , 2003, 170, 3577-3584.	0.8	30
36	Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)-mediated apoptosis in activation-induced T cell death involves calcineurin and protein kinase C, respectively. <i>European Journal of Immunology</i> , 1999, 29, 383-393.	2.9	29

#	ARTICLE	IF	CITATIONS
37	Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1247-1255.	4.9	29
38	Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors. <i>Biochemistry</i> , 2009, 48, 2180-2191.	2.5	29
39	Retinoid receptor-activating ligands are produced within the mouse thymus during postnatal development. <i>European Journal of Immunology</i> , 2008, 38, 147-155.	2.9	28
40	NOXA contributes to the sensitivity of PERK-deficient cells to ER stress. <i>FEBS Letters</i> , 2012, 586, 4023-4030.	2.8	28
41	Recreating complex pathophysiologies in vitro with extracellular matrix surrogates for anticancer therapeutics screening. <i>Drug Discovery Today</i> , 2016, 21, 1521-1531.	6.4	28
42	Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML. <i>Scientific Reports</i> , 2018, 8, 15752.	3.3	26
43	Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.013730.	3.8	25
44	The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , 2016, 49, 74-88.	3.3	22
45	Targeting Trail Towards the Clinic. <i>Current Drug Targets</i> , 2011, 12, 2079-2090.	2.1	21
46	Decorated Macrocycles via Ring-Closing Double-Reductive Amination. Identification of an Apoptosis Inducer of Leukemic Cells That at Least Partially Antagonizes a 5-HT2 Receptor. <i>Organic Letters</i> , 2015, 17, 1672-1675.	4.6	21
47	Is There a Role for Nuclear Factor κ B in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance?. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 38-49.	3.8	19
48	Synthetic constrained peptide selectively binds and antagonizes death receptor 5. <i>FEBS Journal</i> , 2010, 277, 1653-1665.	4.7	19
49	Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing. <i>Drug Discovery Today</i> , 2016, 21, 1464-1471.	6.4	19
50	Targeting AML through DR4 with a novel variant of rhTRAIL. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2216-2231.	3.6	18
51	The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells. <i>Leukemia Research Reports</i> , 2014, 3, 79-82.	0.4	15
52	Identification of an inhibitor of caspase activation from heart extracts; ATP blocks apoptosome formation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 465-474.	4.9	14
53	The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. <i>Cancers</i> , 2011, 3, 1329-1350.	3.7	14
54	Hypoxia and Ischemia Induce Nuclear Condensation and Caspase Activation in Cardiomyocytes. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 728-732.	3.8	10

#	ARTICLE	IF	CITATIONS
55	BCL-2 modulates the unfolded protein response by enhancing splicing of X-box binding protein-1. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 40-45.	2.1	10
56	CD95-mediated alteration in Hsp70 levels is dependent on protein stabilization. <i>Cell Stress and Chaperones</i> , 2005, 10, 59.	2.9	10
57	Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 362-364.	0.7	5
58	Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 662868.	3.7	5
59	Cell Death in HIV Pathogenesis and Its Modulation by Retinoids. <i>Annals of the New York Academy of Sciences</i> , 2001, 946, 95-107.	3.8	4
60	Theranostic drug test incorporating the bone marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy. <i>British Journal of Haematology</i> , 2020, 189, e254-e258.	2.5	4
61	An added dimension to tumour TRAIL sensitivity. <i>Oncoscience</i> , 2015, 2, 906-907.	2.2	4
62	Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy. <i>BMC Genomics</i> , 2014, 15, 1144.	2.8	3
63	Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1876.	3.7	3
64	Macromolecular crowding in the development of a three-dimensional organotypic human breast cancer model. <i>Biomaterials</i> , 2022, 287, 121642.	11.4	3
65	Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 2162.	4.8	2
66	Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)-mediated apoptosis in activation-induced T cell death involves calcineurin and protein kinase C, respectively. <i>European Journal of Immunology</i> , 1999, 29, 383-393.	2.9	1
67	The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia. <i>Blood</i> , 2010, 116, 1841-1841.	1.4	1
68	G2/M Arrest Sensitizes Chronic Myelogenous Leukemia Cells to TRAIL-Induced Apoptosis. <i>Blood</i> , 2010, 116, 4465-4465.	1.4	1
69	Generation of Tumour-stroma Minispheroids for Drug Efficacy Testing. <i>Bio-protocol</i> , 2017, 7, e2091.	0.4	0
70	Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment. <i>Blood</i> , 2018, 132, 2636-2636.	1.4	0
71	Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse. <i>Blood</i> , 2021, 138, 3316-3316.	1.4	0